Abstract

Lipid-free apoA-I and mature spherical HDL have been shown to induce glucose uptake in skeletal muscle. To exploit apoA-I and HDL states for diabetes therapy, further understanding of interaction between muscle and apoA-I is required. This study has examined whether nascent discoidal HDL, in which apoA-I attains a different conformation from mature HDL and lipid-free states, could induce muscle glucose uptake and whether a specific domain of apoA-I can mediate this effect. Using L6 myotubes stimulated with synthetic reconstituted discoidal HDL (rHDL), we show a glucose uptake effect comparable to insulin. Increased plasma membrane GLUT4 levels in ex vivo rHDL-stimulated myofibers from HA-GLUT4-GFP transgenic mice support this observation. rHDL increased phosphorylation of AMP kinase (AMPK) and acetyl-coA carboxylase (ACC) but not Akt. A survey of domain-specific peptides of apoA-I showed that the lipid-free C-terminal 190–243 fragment increases plasma membrane GLUT4, promotes glucose uptake, and activates AMPK signaling but not Akt. This may be explained by changes in α-helical content of 190–243 fragment versus full-length lipid-free apoA-I as assessed by circular dichroism spectroscopy. Discoidal HDL and the 190–243 peptide of apoA-I are potent agonists of glucose uptake in skeletal muscle, and the C-terminal α-helical content of apoA-I may be an important determinant of this effect.

Highlights

  • Lipid-free Apolipoprotein A-I (apoA-I) and mature spherical high-density lipoprotein (HDL) have been shown to induce glucose uptake in skeletal muscle

  • This study analyzed the capability of discoidal HDL and the potency of subdomains of apoA-I to promote translocation of the GLUT4 glucose transporter to the plasma membrane and thereby induce glucose uptake

  • It is clear that discoidal HDL promotes glucose uptake in cultured skeletal muscle, eliciting an effect comparable to insulin

Read more

Summary

Introduction

Lipid-free apoA-I and mature spherical HDL have been shown to induce glucose uptake in skeletal muscle. The rate of glucose uptake in skeletal muscle, the principal site for plasma glucose clearance, is determined by cell surface levels of GLUT4, which is controlled by both the insulin signaling pathway and the AMP kinase (AMPK) contraction-induced pathway [10]. As these are largely independent signaling routes, AMPK represents a therapeutic target for the maintenance of plasma glucose despite insulin resistance [11]. It has been shown that lipid-free apoA-I and spherical HDL can induce glucose uptake in C2C12 myotubes [6] and in human myotubes differentiated from muscle satellite cells from diabetic donors [7] via the activation of AMPK, which provides promise for apoA-I/ HDL as a novel diabetic treatment

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.